CD43 expression is associated with inferior survival in the non-germinal centre B-cell subgroup of diffuse large B-cell lymphoma

Zdravko Mitrovic, Javeed Iqbal, Kai Fu, Lynette M. Smith, Martin Bast, Timothy C. Greiner, Patricia Aoun, James O. Armitage, Julie M. Vose, Dennis D. Weisenburger, Wing C. Chan

Research output: Contribution to journalArticle

10 Scopus citations


We evaluated the prognostic significance of CD43 (SPN), a membrane glycoprotein, in 140 patients with diffuse large B-cell lymphoma (DLBCL) by tissue microarray (TMA) immunostaining, and gene expression profiling (GEP) in 43 patients. CD43 protein was expressed in 19% of the cases and was strongly related to the non-germinal centre B-cell (non-GCB) subgroup by both TMA and GEP. Patients with CD43(+) DLBCL had an inferior 3-year overall survival (OS) compared to those with CD43(-) DLBCL (50% vs. 76%, P = 0·01). Within the non-GCB subgroup, patients with CD43(+) DLBCL had a particularly poor 3-year OS (32% vs. 71%, P < 0·001). Gene set enrichment analysis within the activated B-cell subgroup revealed significant enrichment in the stromal-1 signature in CD43(-) cases. We conclude that CD43 is an adverse prognostic marker in DLBCL, and is preferentially expressed in the non-GCB subgroup. The dismal outcome of CD43(+) cases in the non-GCB subgroup may be explained, at least in part, by a less favourable microenvironment.

Original languageEnglish (US)
Pages (from-to)87-92
Number of pages6
JournalBritish Journal of Haematology
Issue number1
StatePublished - Jul 1 2013



  • CD43 (SPN)
  • Cell of origin
  • Diffuse large B-cell lymphoma
  • Microenvironment
  • Prognostic marker

ASJC Scopus subject areas

  • Hematology

Cite this